key: cord-1008230-j2hmgxbw
authors: El-Sayed, M.S.M.; Jones, T. A.
title: Risk of acute pulmonary embolism in COVID-19 pneumonia compared to community-acquired pneumonia: a retrospective case–control study
date: 2021-03-31
journal: Clin Radiol
DOI: 10.1016/j.crad.2021.03.014
sha: b5603875735a5fcd35932675ab44f09f52000864
doc_id: 1008230
cord_uid: j2hmgxbw

Aim To compare the incidence of pulmonary embolism (PE) in COVID-19 pneumonia and non-COVID-19-related community-acquired pneumonia (CAP) in hospitalised patients. Materials and methods A retrospective case–control study was conducted. This included patients hospitalised with pneumonia and investigated for suspected PE with computed tomography pulmonary angiogram (CTPA). Cases were defined as patients with COVID-19 pneumonia from 1 March 2020 to 17 May 2020; controls were patients with CAP from 5 July 2019 to 31 January 2020. The primary outcome was to determine the risk of developing PE in both groups. Multivariable logistic regression was used to calculate the adjusted odds ratio for PE. Results One hundred and forty-four patients were included; 72 cases (47% male; mean age 59 (±15) years), and 72 controls (56% male; mean age 58 (±20) years). PE was diagnosed in 23.6% of the cases versus 6.9% of the controls. The adjusted odds ratio for PE in hospitalised patients with COVID-19 pneumonia compared with those with CAP was 3.23 (95% confidence interval [CI] 1.04–10.04, p=0.04). Conclusion The odds of developing PE in hospitalised patients with COVID-19 pneumonia are three-times higher than in those with CAP. The results provide a quantitative assessment of the risk of PE in COVID-19 pneumonia, a condition new to healthcare, compared to other forms of pneumonia with a well-established scientific basis.

A IM: T o c om pa re the inc ide nc e of pulm ona ry e m bolis m (P E ) in C O V ID - 1 9 pne um onia a nd non-C O V ID -1 9 -re la te d c om m unity-a c quire d pne um onia (C A P ) in hos pita lis e d pa tie nts .

MA T E R IA L S A N D ME T H O D S : A re tros pe c tive c a s e -c ontrol s tudy wa s c onduc te d.

T his inc lude d pa tie nts hos pita lis e d with pne um onia a nd inve s tig a te d for s us pe c te d P E with c om pute d tom og ra phy pulm ona ry a ng iog ra m (C T P A ). C a s e s we re de fine d a s pa tie nts with C O V ID -1 9 pne um onia from 1 Ma rc h 2 0 20 to 17 Ma y 2 0 2 0 ; c ontrols we re pa tie nts with C A P from 5 J uly 2 0 19 to 3 1 J a nua ry 2 0 2 0 . T he prim a ry outc om e wa s to de te rm ine the ris k of de ve loping P E in both g roups . Multiva ria ble log is tic re g re s s ion wa s us e d to c a lc ula te the a djus te d odds ra tio for P E .

R E S U L T S : O ne hundre d a nd forty-four pa tie nts we re inc lude d; 7 2 c a s e s (4 7 % m a le ; m e a n a g e 5 9 (± 15 ) ye a rs ), a nd 7 2 c ontrols (5 6 % m a le ; m e a n a g e 5 8 (± 2 0 ) ye a rs ). P E wa s dia g nos e d in 2 3 .6 % of the c a s e s ve rs us 6 .9% of the c ontrols . T he a djus te d odds ra tio for P E in hos pita lis e d pa tie nts with C O V ID -1 9 pne um onia c om pa re d with thos e with C A P wa s 3 . c om m only m is s e d dia g nos e s in c linic a l pra c tic e ,(2 ) a nd is the g re a te s t pre ve nta ble J o u r n a l P r e -p r o o f cause of hospital mortality. (3, 4) The annual incidence of PE is estimated at 39-115 cases per 100,000 population with a mortality rate of 30-35% if untreated. (5, 6) There is mounting evidence in the literature of an increased incidence of PE in hospitalised patients with SARS-CoV-2 infection.(7-18) This novel coronavirus can cause pneumonia of varying degrees of severity; however, studies prior to the COVID-19 pandemic also suggested an increased incidence of PE in hospitalised patients with community-acquired pneumonia (CAP). (19) (20) (21) Since pneumonia itself is a risk factor for PE,(22,23) the present study investigated the risk of PE in COVID-19 pneumonia versus CAP in hospitalised patients to determine whether the reported increased PE incidence in SARS-CoV-2 infection is above that seen in other forms of pneumonia.

A retrospective case-control study was undertaken to compare the incidence of PE in COVID-19 pneumonia and CAP in the setting of hospitalised patients investigated with a computed tomography (CT) pulmonary angiogram (CTPA). The primary outcome was to detect the risk of developing PE in both groups.

The current literature suggests an incidence of PE in 20.6-40% and 3.5-5% of COVID-19 pneumonia patients and CAP patients, respectively, when investigated with CTPA. (9, 10, (16) (17) (18) (19) (20) (21) Sample size was powered to detect a 2% effect size for CTPA scans performed between 1 March and 17 May 2020 with reports containing the keywords "COVID", "pneumonia", "infection", "ground glass", "consolidation", "airspace", "opacity", "opacities", OR "opacification". All patients who met the eligibility criteria for the COVID-19 pneumonia group were included. This resulted in 72 eligible patients.

Controls were identified using the exact same keyword search criteria, except for "COVID". The first 72 eligible patients in reverse chronological order prior to 1 February 2020 were included. This sufficient sample size was achieved between 5

July 2019 and 31 January 2020. It is unlikely that this sample included any patients with SARS-CoV-2 infection as the UK declared its first COVID-19 patients on 30 January 2020.(24) The selected time periods for both groups were sufficiently close to minimise differences in healthcare teams, management practices, and equipment that they would have been exposed to. The censoring date was 22 June 2020. This ensured that all patients had at least 5 weeks of follow-up to ensure satisfactory data collection. 

For the COVID-19 pneumonia group, the CRIS keyword search identified 382 potential patients during the period between 1 March 2020 and 17 May 2020. Of these, 310 (81%) were excluded as they did not meet the study's eligibility criteria (Fig. 2) . This resulted in 72 eligible patients in the COVID-19 pneumonia group. For the control group, the CRIS keyword search yielded 1,201 potential patients during the period between 5 July 2019 and 31 January 2020. Of these, 1,129 patients (94%) were excluded as they did not meet the study's eligibility criteria (Fig. 2) .

Eventually, 72 consecutive eligible patients were identified and included in the CAP group.

Twelve of the 72 (17%) scans in the COVID-19 pneumonia group and 10/72 (14%) scans in the CAP group showed artefacts at the subsegmental level due to suboptimal contrast opacification and/or respiratory motion artefact. These were included in the study, as there was either a positive diagnosis of PE proximal to the subsegmental level or when the scan was negative for PE, there was no ongoing clinical concern of or a proven PE on the patients' follow-up.

The baseline characteristics of both groups are summarised in table 1. There was no significant difference in the age and sex between the groups (p=0.62 and 0.40, respectively). The COVID-19 pneumonia group showed a more diverse range of ethnicities with black, Asian, and minority ethnic (BAME) groups comprising 50%, compared to 28% of the CAP group (p=0.02). There was no significant difference in most of the co-morbidities between the groups, except for cardiovascular diseases, which were more prevalent with COVID-19 pneumonia (p=0.04). Moreover, patients with COVID-19 pneumonia had more risk factors for PE, specifically a higher prevalence of obesity (p=0.04), and longer period of hospitalisation prior to acquiring the CTPA (p=0.001). In both groups, VTE prophylaxis was given appropriately to all the patients who were later confirmed to have PE. There were no pregnant patients in the cohort who would tend to be investigated with ventilation-perfusion singlephoto-emission computed tomography (VQ SPECT) krypton-81m as the ventilation agent.

PE was confirmed in 17/72 (23.6%) of the cases and in 5/72 (6.9%) of the controls (p=0.005). The crude odds ratio for PE in the hospitalised patients with COVID-19 pneumonia compared with those with CAP was 4.14 (95% CI 1.44-11.94, p=0.009).

After adjustment for potential confounding factors, the odds ratio among hospitalised patients with COVID-19 pneumonia was 3.23 (95% CI 1.04-10.04, p=0.04). The goodness-of-fit test Hosmer-Lemeshow of the multivariable logistic regression model was 0.97. The other confounding variables did not contribute significantly to the logistic regression model, which showed that COVID-19 pneumonia was an independent risk factor for PE (Table 2) .

Regarding patients who required higher levels of care, there was no significant difference in the proportion of patients who required critical care management in both J o u r n a l P r e -p r o o f groups (p=0.16), even amongst those diagnosed with PE (p=0.61); however, within the COVID-19 pneumonia group, critical care management was required for a significantly greater proportion of the patients with PE than those without PE (p=0.004; Table 3 ).

By the end of the data collection period on 22 June 2020, all the patients in the study had either been discharged from hospital alive or died. The mortality rate was higher in the COVID-19 pneumonia group (19%) compared to the CAP group (11%); however, this did not reach statistical significance (p=0.17). There was no significant difference at all in the mortality rate between those with confirmed PE between the groups (p=0.87). Furthermore, there was no significant difference in the mortality rates amongst patients with COVID-19 pneumonia whether they had PE or not (p=0.63; Table 3 ).

When there was a confirmed diagnosis of PE, the commonest locations of the most proximal filling defect in both groups were in the lobar vessels, followed by the segmental vessels. Only 17.7% of the positive scans in patients with COVID-19 pneumonia showed PE in the central vessels, whilst none of the patients with CAP developd central PE; this difference was not statistically significant (p=0.31; Table 3 ).

The median D-dimer level was approximately 500 µg/l higher in the COVID-19 pneumonia group (p=0.02; Table 4 ). ROC curve was derived for the entire study 

Birmingham City Hospital currently employs a standard D-dimer cut-off level of 500 µg/l for all age groups rather than an age-adjusted cut-off in patients >50 years of age. The sensitivity, specificity, PPV, and NPV for both the standard and ageadjusted D-dimer cut-offs were calculated ( Table 4 ). The analysis showed that adopting an age-adjusted D-dimer cut-off improved the specificity and PPV in both groups without compromising the sensitivity or the NPV. Implementing this approach would have avoided unnecessary CTPA in 1/72 patients with COVID-19 pneumonia (1.4%) and in 3/72 patients with CAP (4.2%).

Pneumonia is a known risk factor for PE, even before the COVID-19

pandemic.(22,23) A high incidence of PE in patients with SARS-CoV-2 infection has been recently reported in the literature;(7-18) however, given the excessive number of infected cases during the pandemic, comparison with a control group of patients with classical pneumonia would provide more confirmation as to whether the perceived high incidence is true. This study shows that the odds of developing PE in hospitalised patients with COVID-19 pneumonia are three-times higher than in those hospitalised with CAP. The study results may guide the clinical teams to gauge the risk of PE in COVID-19 pneumonia in comparison with the risk of PE in the classical CAP.

Male sex, BAME backgrounds, and multiple co-morbidities are recognised risk factors for developing severe COVID-19 pneumonia. (25) (26) (27) (28) This was demonstrated in the present study, which identified that a higher proportion of these patients that required hospitalisation were from BAME communities than in the CAP group. The present data also showed that cardiovascular diseases, obesity, and longer In the present study, all the PE events occurred despite the appropriate standard of care VTE prophylaxis. This is in line with the other published data, (8, 11, 12, 15, 17) and supports that COVID-19 pneumonia may be an independent risk factor for PE. It is possible that the standard doses of VTE prophylaxis are insufficient, and that higher dose regimens may be more efficacious.

The present study supports other published data that patients with COVID-19 pneumonia who develop PE are more likely to require critical care management. (17, 18) Therefore, these patients may require close monitoring. An interesting finding in the present data is that in patients with confirmed PE, there was no difference in the mortality rates between the COVID-19 pneumonia and CAP groups. More importantly, there was no difference in the mortality rates amongst patients with COVID-19 pneumonia, whether they had PE or not. As this study only assessed patients in whom a CTPA was performed, it suggests that PE in COVID-19 pneumonia may not adversely impact upon mortality rate, as long as it is promptly recognised and treated. Even though the number of patients in the present study is too small to confirm this finding, it is particularly noteworthy as, unlike in CAP, there J o u r n a l P r e -p r o o f is no effective treatment for COVID-19 pneumonia to date. The treatment for PE, however, is effective and so the diagnosis should not be missed.

A D-dimer level of 1,640 µg/l was the optimal cut-off value according to the present data; however, this level is only related to the study sample and is different to the levels suggested elsewhere. (16) After assessing the utility of an age-adjusted Ddimer cut-off for suspected PE in patients with COVID-19 pneumonia, the specificity and PPV for PE increased, without compromising the sensitivity or NPV; however the yield was lower in COVID-19 pneumonia compared to CAP, due to the generally higher D-dimer levels in the former. Implementing an age-adjusted D-dimer cut-off could have avoided unnecessary CTPA in 1.4% of the patients with COVID-19 pneumonia in the present sample. Prior to the COVID-19 pandemic, the use of an age-adjusted D-dimer cut-off in suspected PE was established by meta-analysis and recommended by the major guidelines.(29-32) Its usage is recommended for suspected PE in COVID-19 pneumonia patients when appropriate.

The present study had limitations and strengths. Regarding limitations, the study was retrospective. Imaging was only performed in patients with clinical signs and symptoms suggestive of PE; therefore, it is conceivable that patients with subclinical features of PE may not have undergone further imaging. The results of this study may not be generalisable to the community setting as the incidence of PE in nonhospitalised individuals with COVID-19 pneumonia was not investigated; however, the study has many strengths as the diagnoses of COVID-19 pneumonia, CAP, and PE were confirmed objectively. Data were collected from two general hospitals in a major city, which draws from a wide, ethnically diverse population. The results of this study may therefore be transferable to various general population groups within a hospital setting.

In conclusion, the risk of PE in hospitalised patients with COVID-19 pneumonia is higher than those with CAP (adjusted odds ratio 3.23). This demonstrates the impact of this widespread illness on the healthcare resources. Furthermore, the results provide a quantitative assessment of the risk of PE in COVID-19 pneumonia, a condition new to healthcare, compared to other forms of pneumonia with a wellestablished scientific basis. 

Pulmonary embolism, part I: epidemiology, risk factors and risk stratification, pathophysiology, clinical presentation, diagnosis and nonthrombotic pulmonary embolism

Diagnostic error in medicine: analysis of 583 physician-reported errors

Thromboembolism: an under appreciated cause of death

Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

Global burden of thrombosis: epidemiologic aspects

Pulmonary embolism: what have we learned since Virchow? Natural history, pathophysiology, and diagnosis

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

Thrombotic complications of patients admitted to intensive care with COVID-19 at a teaching hospital in the United Kingdom

Pulmonary thromboembolic disease in COVID-19 patients on CT pulmonary angiography -prevalence, pattern of disease and relationship to D-dimer

Diagnosis, prevention, and treatment of thromboembolic complications in COVID-19: report of the National Institute for Public Health of the Netherlands

High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study

Incidence of venous thromboembolism in hospitalised patients with COVID-19

Pulmonary embolism in COVID-19 patients: awareness of an increased prevalence

COVID-19: an updated analysis

Pulmonary embolism in patients with

Covid-19 pneumonia

Acute pulmonary embolism in COVID-19 patients on CT angiography and relationship to D-dimer levels

Acute pulmonary embolism and COVID-19

Acute pulmonary embolism associated with COVID-19 pneumonia detected by pulmonary CT angiography

Clinical characteristics of pulmonary embolism with concomitant pneumonia

The incidence and significance of pulmonary emboli at the time of presentation of community-acquired pneumonia

Risk factors for pulmonary embolism in patients preliminarily diagnosed with community-acquired pneumonia: a prospective cohort study

Pneumonia and risk of venous thrombosis: results from the MEGA study

Risk of deep vein thrombosis and pulmonary embolism after acute infection in a community setting

Novel coronavirus disease (Covid-19): the first two patients in the UK with person to person transmission

Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of General Practitioners Research and Surveillance Centre primary care network: a cross-sectional study

Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study

Evidence mounts on the disproportionate effect of COVID-19 on ethnic minorities

Characteristics and diagnosis rate of 5630

subjects receiving SARS-CoV-2 nucleic acid tests from Wuhan

Evaluation of patients with suspected acute pulmonary embolism: best practice advice from the Clinical Guidelines Committee of the American College of Physicians

Venous thromboembolic disease: diagnosis, management and thrombophilia testing. NICE Guideline 158

• Πυλ µ οναρψ ε µ βολ ισµ ρισκ ισ ινχρε ασε δ ιν πατιε ντσ ηοσπιταλ ισε δ ωιτη πνε υµ ονια

• Τηε ρισκ ισ ηιγ ηε ρ ιφ τηε πνε υµ ονια ισ δυε το ΣΑΡ Σ−Χος −2 ινφε χτιον

• Χοµ παρε δ ωιτη τηε χλ ασσιχαλ χοµ µ υνιτψ−αχθυιρε δ πνε υµ ονια, τηε οδδσ ρατιο ισ 3

The authors declare no conflicts of interest.

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

OR a (95% CI) p-Value J o u r n a l P r e -p r o o f

☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.